Gupta Rajesh K
Biologics Quality & Regulatory Consultants, LLC, North Potomac, MD 20878, USA.
J Pharm Sci. 2025 Feb;114(2):690-700. doi: 10.1016/j.xphs.2024.12.011. Epub 2024 Dec 20.
Biological Standardization has been pivotal to the success of traditional biological products, such as vaccines, antitoxins, and immune globulins, by ensuring their quality and consistency across manufacturers worldwide. The principles of biological standardization have similarly supported the development and manufacture of safe and effective modern biological products, including hormone, therapeutic protein, and monoclonal antibody products, and continue to play a vital role in advancing new cutting-edge biological products, such as tissue, cellular, and gene-therapy products. Biological standardization started with the physical standards ensuring the reliability and suitability of methods used to test biological products and science of bioassays or biological methods and related biostatistics providing a framework for evaluating biological, functional activity or potency of these products. It expanded to include written standards defining the quality requirements for manufacturing and regulation of biological standards. Due to the shift in the biologics industry from public health to commercial-driven enterprises during the past 50 years, the biological standardization program has evolved to include the product-specific reference standards and harmonization of physical standards. The global success of conventional vaccines in controlling numerous deadly infectious diseases can largely be attributed to the availability of physical and written international standards developed through a strong biological standardization program. This article explores the evolution of biological standardization for more than a century, its scientific and regulatory principles, challenges from disruption in international standardization efforts, and future perspectives for the field.
生物标准化对于传统生物制品(如疫苗、抗毒素和免疫球蛋白)的成功至关重要,它确保了全球各生产商生产的此类产品的质量和一致性。生物标准化的原则同样也支持了安全有效的现代生物制品(包括激素、治疗性蛋白质和单克隆抗体产品)的研发与生产,并且在推动新型前沿生物制品(如组织、细胞和基因治疗产品)的发展方面继续发挥着至关重要的作用。生物标准化始于物理标准,这些标准确保了用于检测生物制品的方法的可靠性和适用性,以及生物测定或生物学方法及相关生物统计学的科学性,它们为评估这些产品的生物学、功能活性或效价提供了框架。后来它扩展到包括定义生物制品生产质量要求和生物标准监管的书面标准。由于在过去50年里生物制品行业从公共卫生领域转向了商业驱动型企业,生物标准化计划已经发展到包括特定产品的参考标准和物理标准的协调统一。传统疫苗在控制众多致命传染病方面取得的全球成功,很大程度上归功于通过强有力的生物标准化计划制定的物理和书面国际标准。本文探讨了一个多世纪以来生物标准化的演变历程、其科学和监管原则、国际标准化工作中断带来的挑战以及该领域的未来展望。